cligosiban
highly-affinity nonpeptide oxytocin receptor antagonist
Also Known As:
5-(3-(3-(2-Chloro-4-fluorophenoxy)-1-azetidinyl)-5-(methoxymethyl)-4H-1,2,4-triazol-4-yl)-2-methoxypyridine; Pyridine, 5-(3-(3-(2-chloro-4-fluorophenoxy)-1-azetidinyl)-5-(methoxymethyl)-4H-1,2,4-triazol-4-yl)-2-methoxy-
Networked: 7
relevant articles (0 outcomes,
4 trials/studies)
Bio-Agent Context: Research Results
Experts
| 1. | Muirhead, Gary J:
5 articles
(11/2019 - 11/2018)
|
| 2. | Osterloh, Ian H:
5 articles
(11/2019 - 11/2018)
|
| 3. | Althof, Stanley:
2 articles
(01/2019 - 01/2019)
|
| 4. | Whaley, Steven:
2 articles
(01/2019 - 11/2018)
|
| 5. | van den Berg, Frans:
2 articles
(01/2019 - 11/2018)
|
| 6. | Gen, Soei:
1 article
(09/2021)
|
| 7. | Hashimoto, Naozumi:
1 article
(09/2021)
|
| 8. | Hori, Kazumi:
1 article
(09/2021)
|
| 9. | Kodama, Yuta:
1 article
(09/2021)
|
| 10. | Matsubara, Daisuke:
1 article
(09/2021)
|
Related Diseases
| 1. | Premature Ejaculation
11/01/2019
- " Response to Letter to the Editor Regarding "Cligosiban for Premature Ejaculation: Success, Failure, or Insufficiently Tested?"" 11/01/2019
- " Cligosiban for Premature Ejaculation: Success, Failure, or Insufficiently Tested?" 01/01/2019
- " The Oxytocin Antagonist Cligosiban Fails to Prolong Intravaginal Ejaculatory Latency in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Phase IIb trial (PEDRIX). " 01/01/2019
- " The Oxytocin Antagonist Cligosiban Fails to Prolong Intravaginal Ejaculatory Latency in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Phase IIb trial (PEDRIX)." 01/01/2019
- " The Oxytocin Antagonist Cligosiban Prolongs Intravaginal Ejaculatory Latency and Improves Patient-Reported Outcomes in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Trial (PEPIX). "
|
| 2. | Neoplasms (Cancer)
|
|
Related Drugs and Biologics
Related Therapies and Procedures